Underlying Treatment of Myeloproliferative Neoplasms
Underlying Treatment of Myeloproliferative Neoplasms
January 2016
- A 59-year-old male presents to his physician with symptoms of fatigue and abdominal pain lasting 3 months; he also reports increased bruising
- Physical Exam: Spleen is palpable, 6 cm. below left costal margin
- CBC with differential
- RBC; 3.20 x 1012/L
- HGB; 9.3 g/dL
- HCT; 34%
- MCV; 93.1 fL
- WBC; 12.1 x 109/L
- PLT; 247 x 109/L
- PB BLASTS; 0%
- Genetic testing showsJAK2V617Fmutation
- Bone marrow biopsy showed megakaryocyte proliferation and atypia with evidence of reticulin fibrosis
NCCN guidelines indicate rusfertide for patients who are intolerant to phlebotomy or who receive frequent phlebotomy, regardless of risk status.
The FDA designation is for LYT-200 plus a hypomethylating agent for relapsed/refractory high-risk myelodysplastic syndromes.
The application for bezuclastinib in advanced systemic mastocytosisis is supported by data from the APEX trial.